KR101021752B1 - Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제 및 억제 방법 - Google Patents

Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제 및 억제 방법 Download PDF

Info

Publication number
KR101021752B1
KR101021752B1 KR1020047018685A KR20047018685A KR101021752B1 KR 101021752 B1 KR101021752 B1 KR 101021752B1 KR 1020047018685 A KR1020047018685 A KR 1020047018685A KR 20047018685 A KR20047018685 A KR 20047018685A KR 101021752 B1 KR101021752 B1 KR 101021752B1
Authority
KR
South Korea
Prior art keywords
inhibitors
formula
agents
sglt2
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020047018685A
Other languages
English (en)
Korean (ko)
Other versions
KR20050004161A (ko
Inventor
브루스 엘즈워스
윌리엄 엔. 워시번
필립 엠. 셔
강 우
웨이 멩
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29582046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101021752(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20050004161A publication Critical patent/KR20050004161A/ko
Application granted granted Critical
Publication of KR101021752B1 publication Critical patent/KR101021752B1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020047018685A 2002-05-20 2003-05-15 Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제 및 억제 방법 Ceased KR101021752B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/151,436 2002-05-20
US10/151,436 US6515117B2 (en) 1999-10-12 2002-05-20 C-aryl glucoside SGLT2 inhibitors and method
PCT/US2003/015591 WO2003099836A1 (en) 2002-05-20 2003-05-15 C-aryl glucoside sglt2 inhibitors and method

Publications (2)

Publication Number Publication Date
KR20050004161A KR20050004161A (ko) 2005-01-12
KR101021752B1 true KR101021752B1 (ko) 2011-03-15

Family

ID=29582046

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047018685A Ceased KR101021752B1 (ko) 2002-05-20 2003-05-15 Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제 및 억제 방법

Country Status (39)

Country Link
US (1) US6515117B2 (enrdf_load_stackoverflow)
EP (1) EP1506211B1 (enrdf_load_stackoverflow)
JP (4) JP5090621B2 (enrdf_load_stackoverflow)
KR (1) KR101021752B1 (enrdf_load_stackoverflow)
CN (5) CN102627676B (enrdf_load_stackoverflow)
AR (1) AR040032A1 (enrdf_load_stackoverflow)
AT (1) ATE353334T1 (enrdf_load_stackoverflow)
AU (1) AU2003237886B2 (enrdf_load_stackoverflow)
BE (2) BE2013C025I2 (enrdf_load_stackoverflow)
BR (2) BR122017015091B8 (enrdf_load_stackoverflow)
CA (1) CA2486539C (enrdf_load_stackoverflow)
CY (3) CY1106465T1 (enrdf_load_stackoverflow)
DE (1) DE60311649T2 (enrdf_load_stackoverflow)
DK (1) DK1506211T3 (enrdf_load_stackoverflow)
ES (1) ES2280759T3 (enrdf_load_stackoverflow)
FR (2) FR13C0022I2 (enrdf_load_stackoverflow)
GE (1) GEP20084403B (enrdf_load_stackoverflow)
HK (1) HK1205120A1 (enrdf_load_stackoverflow)
HR (1) HRP20041084B1 (enrdf_load_stackoverflow)
IL (1) IL165119A0 (enrdf_load_stackoverflow)
IN (1) IN2004DE03573A (enrdf_load_stackoverflow)
IS (1) IS7529A (enrdf_load_stackoverflow)
LT (1) LTC1506211I2 (enrdf_load_stackoverflow)
LU (2) LU92182I2 (enrdf_load_stackoverflow)
ME (2) ME00091B (enrdf_load_stackoverflow)
MX (1) MX249731B (enrdf_load_stackoverflow)
MY (1) MY142499A (enrdf_load_stackoverflow)
NO (4) NO329107B1 (enrdf_load_stackoverflow)
NZ (1) NZ536605A (enrdf_load_stackoverflow)
PE (1) PE20040760A1 (enrdf_load_stackoverflow)
PL (1) PL210304B1 (enrdf_load_stackoverflow)
PT (1) PT1506211E (enrdf_load_stackoverflow)
RS (1) RS51469B (enrdf_load_stackoverflow)
RU (4) RU2337916C2 (enrdf_load_stackoverflow)
SI (1) SI1506211T1 (enrdf_load_stackoverflow)
TW (1) TWI310770B (enrdf_load_stackoverflow)
UA (1) UA77306C2 (enrdf_load_stackoverflow)
WO (1) WO2003099836A1 (enrdf_load_stackoverflow)
ZA (1) ZA200409295B (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
KR20200028796A (ko) 2018-09-07 2020-03-17 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물

Families Citing this family (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
DE60142632D1 (de) 2000-11-30 2010-09-02 Novodermix Internat Ltd Heilung von wunden
ES2390061T4 (es) * 2001-02-24 2013-04-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derivados de xantina, su preparación y uso como medicamentos
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP4590159B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
EP1432720A1 (en) * 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003272903A1 (en) * 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7375213B2 (en) * 2003-01-03 2008-05-20 Bristol-Myers Squibb Company Methods of producing C-aryl glucoside SGLT2 inhibitors
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
PT1980560E (pt) 2003-03-14 2011-06-29 Astellas Pharma Inc Derivados de c-glicósido para o tratamento da diabetes
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EP2514756B1 (en) * 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
EA009768B1 (ru) * 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
US7094764B2 (en) * 2003-08-01 2006-08-22 Janssen Pharmaceutica N.V. Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
EA010655B1 (ru) * 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005219777B2 (en) * 2004-03-04 2011-02-03 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
CA2557801C (en) 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004034690A1 (de) * 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CA2581922A1 (en) * 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587639A1 (en) * 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) * 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
ES2319461T3 (es) * 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
ES2334940T3 (es) * 2005-02-23 2010-03-17 Boehringer Ingelheim International Gmbh Derivados de ((hetero)ariletinilbencil)benceno sustituidos con glucopiranosilo y uso de los mismos como inhibidores del cotransportador 2 de glucosa dependiente de sodio (sglt2).
WO2006108842A1 (en) * 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
ATE468347T1 (de) * 2005-07-27 2010-06-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)- benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters (sglt)
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1924571B1 (en) * 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2007028814A1 (en) * 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
AR056195A1 (es) * 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
MEP7609A (en) * 2005-12-28 2011-12-20 Therapeutic agent for diabetes
TW200801029A (en) 2006-02-15 2008-01-01 Boehringer Ingelheim Int Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA015687B1 (ru) 2006-05-04 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US8039441B2 (en) 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
CA2662064A1 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
CN101522699A (zh) 2006-10-13 2009-09-02 中外制药株式会社 硫葡萄糖螺缩酮衍生物、及其作为糖尿病治疗药的应用
EP2086991A1 (en) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CA2671699C (en) * 2006-12-04 2014-07-08 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
WO2008070692A2 (en) 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
JPWO2008075736A1 (ja) * 2006-12-21 2010-04-15 アステラス製薬株式会社 Ｃ−グリコシド誘導体の製造方法及びその合成中間体
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
AU2014201239B2 (en) * 2007-03-22 2016-03-10 Astrazeneca Ab Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
PT2183263E (pt) * 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090603A1 (es) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JP4809931B2 (ja) * 2007-08-23 2011-11-09 セラコス・インコーポレイテッド ベンジルベンゼン誘導体およびその使用方法
UA105480C2 (uk) * 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
PE20091211A1 (es) * 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) * 2007-12-27 2015-03-04 阿斯利康公司 Sglt2 抑制剂的晶体结构及其制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CA2711673A1 (en) * 2008-01-31 2009-08-06 Astellas Pharma Inc. Pharmaceutical compositions for treating fatty liver disease
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
EP2291189B1 (en) * 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
WO2009143010A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
WO2009143021A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9061060B2 (en) * 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2735562C (en) * 2008-08-15 2017-10-17 Boehringer Ingelheim International Gmbh Dpp-4 inhibitors for wound healing
LT2324002T (lt) * 2008-08-22 2016-12-27 Theracos Sub, Llc Sglt2 inhibitorių gavimo būdas
SI2334687T1 (sl) * 2008-08-28 2012-03-30 Pfizer Dioksa biciklo oktan triol derivati
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
CA2737830A1 (en) * 2008-09-19 2010-03-25 Novartis Ag Glycoside derivatives and uses thereof
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2395983B1 (en) 2009-02-13 2020-04-08 Boehringer Ingelheim International GmbH Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AP2011005780A0 (en) * 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient.
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
PH12016501607B1 (en) 2009-02-13 2024-02-21 Boehringer Ingelheim Int Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
CA2752212C (en) * 2009-02-23 2016-08-16 Taisho Pharmaceutical Co., Ltd. 4-isopropylphenyl glucitol compounds as sglt1 inhibitors
EP2226076A1 (de) 2009-02-25 2010-09-08 Henning Vollert Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
WO2010112437A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2010138535A1 (en) * 2009-05-27 2010-12-02 Bristol-Myers Squibb Company Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
DK2451797T3 (da) 2009-07-10 2013-06-24 Janssen Pharmaceutica Nv Fremgangsmåde til krystallisation for 1-(b-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-fluorphenyl)-2- thienylmethyl]benzen
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
ES2546762T3 (es) * 2009-09-30 2015-09-28 Boehringer Ingelheim International Gmbh Procedimientos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo
ES2596202T3 (es) * 2009-09-30 2017-01-05 Boehringer Ingelheim International Gmbh Método para la preparación de una forma cristalina de 1-cloro-4-(ß-D-glucopiranos-1-il)-2-[4-((S)-tetrahidrofuran-3-iloxi)-bencil]-benceno
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EA024368B1 (ru) * 2009-10-14 2016-09-30 Янссен Фармацевтика Нв Процесс получения соединений для применения в качестве ингибиторов sglt2
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
HUE040486T2 (hu) * 2009-11-13 2019-03-28 Astrazeneca Ab Kétrétegû tabletta készítmények
CN102740839B (zh) 2009-11-13 2015-05-06 阿斯利康(瑞典)有限公司 立即释放片剂
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
US20130052266A1 (en) 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
JO3577B1 (ar) 2010-05-11 2020-07-05 Janssen Pharmaceutica Nv صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
CN105541849B (zh) 2010-08-12 2018-03-23 勃林格殷格翰国际有限公司 6‑环烷基‑1,5‑二氢‑吡唑并[3,4‑d]嘧啶‑4‑酮衍生物及其作为PDE9A抑制剂的用途
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2012106303A1 (en) 2011-02-01 2012-08-09 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102643256B (zh) 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN102167715B (zh) * 2011-03-07 2013-04-24 上海惠斯生物科技有限公司 一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2832938C (en) 2011-04-13 2019-09-03 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
KR101609859B1 (ko) * 2011-04-25 2016-04-07 베이징 프릴루드 팜. 에스씨아이. & 테크. 씨오., 엘티디. 소듐-의존적 포도당 운반 단백질의 억제제 및 이의 제조방법 및 용도
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
MX2013013734A (es) * 2011-05-26 2014-02-27 Tfchem Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo.
CN103596574A (zh) 2011-06-03 2014-02-19 勃林格殷格翰国际有限公司 在精神安定剂治疗的患者中治疗代谢障碍的sglt2抑制剂
WO2012163546A1 (en) 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2529742B1 (en) 2011-06-03 2013-11-20 ratiopharm GmbH Pharmaceutical composition comprising dapagliflozin and cyclodextrin
JP5875678B2 (ja) 2011-06-25 2016-03-02 山東軒竹医薬科技有限公司 Ｃ−グルコシド誘導体
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
CN103889429B (zh) * 2011-10-31 2016-10-19 台湾神隆股份有限公司 Sglt2抑制剂的结晶和非结晶形式
EP2597090A1 (en) 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
JP2015500887A (ja) 2011-12-22 2015-01-08 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物、組成物および使用方法
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013178064A1 (zh) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
EP3549587A1 (de) 2012-06-30 2019-10-09 BioActive Food GmbH Zusammensetzung zur behandlung von hyperglykämischen erkrankungen
SG11201501510SA (en) * 2012-08-30 2015-04-29 Taisho Pharmaceutical Co Ltd Combinations of sglt2 inhibitors and antihypertensive drugs
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP2968375B1 (en) 2013-03-14 2019-06-12 MSD International GmbH Methods for preparing sglt2 inhibitors
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
HK1215398A1 (zh) 2013-04-05 2016-08-26 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014170383A1 (en) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015040571A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Process for the preparation of dapagliflozin
US20160237054A1 (en) * 2013-09-27 2016-08-18 Sun Pharmaceutical Industries Limited Process for the purification of dapagliflozin
EP2895490B1 (en) 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
WO2015063726A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
CA3163455A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CN106349201B (zh) * 2014-01-03 2018-09-18 山东轩竹医药科技有限公司 光学纯的苄基-4-氯苯基的c-糖苷衍生物
HUE062714T2 (hu) 2014-01-23 2023-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2 inhibitorok kutyafélék anyagcserezavarainak kezelésére
CN103739581B (zh) * 2014-01-23 2016-11-23 中国药科大学 C-芳基葡萄糖苷sglt2抑制剂
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
IN2014MU00626A (enrdf_load_stackoverflow) * 2014-02-21 2015-09-25 Cadila Healthcare Ltd
US20170056365A1 (en) 2014-02-28 2017-03-02 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3114115A4 (en) * 2014-03-06 2017-08-23 MSN Laboratories Private Limited Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof
PL3125882T3 (pl) 2014-04-01 2020-10-19 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
ES2900843T3 (es) * 2014-05-16 2022-03-18 Astrazeneca Ab Método para suprimir la secreción de glucagón de un inhibidor de sglt2
US9676741B1 (en) 2014-06-23 2017-06-13 Sun Pharmaceutical Industries Limited Co-crystal of dapagliflozin with citric acid
MX388192B (es) 2014-09-25 2025-03-19 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de combinación y/o prevención de trastornos metabólicos en animales equinos.
CA2961148A1 (en) 2014-09-25 2016-03-31 Astrazeneca Ab Use of a combination of an omega-3 fatty acid and an sglt-2 inhibitor for the treatment of non-alcoholic liver disease
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
CN104478839A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种达格列净的合成方法
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
PL3227310T3 (pl) 2014-12-03 2020-02-28 Glycomimetics, Inc. Heterodwufunkcyjne inhibitory selektyn E i receptorów chemokinowych CXCR4”
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN104529970A (zh) * 2015-01-08 2015-04-22 江苏联环药业股份有限公司 制备达格列净的方法
CN104530149A (zh) * 2015-01-14 2015-04-22 佛山市赛维斯医药科技有限公司 卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478966A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478959A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478957A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104478963A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯s-葡萄糖苷结构的化合物及其用途
CN104478965A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497070A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
WO2016128995A1 (en) 2015-02-09 2016-08-18 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
WO2016178148A1 (en) * 2015-05-05 2016-11-10 Glenmark Pharmaceuticals Limited Process for preparation of dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN104961715B (zh) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 一种达格列净的制备方法
EP3349762B1 (en) 2015-09-15 2021-08-25 Laurus Labs Limited Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CZ2015729A3 (cs) 2015-10-13 2017-04-26 Zentiva, K.S. Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN105218329B (zh) * 2015-10-15 2017-05-03 上海应用技术学院 一种列净类似物中间体及其制备方法
EP3362055B1 (en) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
US9845303B2 (en) 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
PT3404033T (pt) * 2016-01-04 2020-10-30 Jeil Pharmaceutical Co Ltd Derivado de c-glucósido que contém um anel de fenilo fundido ou um sal farmaceuticamente aceitável do mesmo, processo para preparação do mesmo e composição farmacêutica que compreende o mesmo
WO2017118945A1 (en) 2016-01-08 2017-07-13 Lupin Limited Premix of dapagliflozin and process for the preparation thereof
WO2017127422A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US20190110994A1 (en) 2016-03-31 2019-04-18 Lupin Limited Pharmaceutical composition of dapagliflozin
CN107304194A (zh) * 2016-04-20 2017-10-31 扬子江药业集团上海海尼药业有限公司 制备达格列净的方法
WO2017202264A1 (zh) * 2016-05-24 2017-11-30 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法和用途
WO2017203229A1 (en) 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
WO2018029611A1 (en) * 2016-08-09 2018-02-15 Laurus Labs Limited Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
WO2018029264A1 (en) 2016-08-10 2018-02-15 Amneal Pharmaceuticals Company Gmbh Process for preparation of dapagliflozin and intermediates thereof
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
JP2019531320A (ja) 2016-10-19 2019-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｓａｏ／ｖａｐ−１阻害剤とｓｇｌｔ２阻害剤とを含む組合せ、その使用
KR20230162125A (ko) 2016-11-10 2023-11-28 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
KR20180058510A (ko) 2016-11-24 2018-06-01 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
CN108218928B (zh) * 2016-12-13 2020-06-30 华润双鹤药业股份有限公司 葡萄糖苷的二环衍生物及其制备方法和用途
WO2018142422A1 (en) * 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy
US11312740B2 (en) 2017-05-09 2022-04-26 Piramal Pharma Limited Process for the preparation of SGLT2 inhibitors and intermediates thereof
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
PT3716979T (pt) * 2017-11-30 2025-07-14 Idorsia Pharmaceuticals Ltd Combinação de um derivado de 4-pirimidinassulfamida com um inibidor de sglt-2 para o tratamento de doenças relacionadas com a endotelina
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
JP2021520394A (ja) 2018-04-17 2021-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、処置方法及びその使用
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
EP3810623A1 (en) 2018-06-25 2021-04-28 Pharmathen S.A. A novel process for the preparation of sglt-2 inhibitors
KR20210034039A (ko) * 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
PL3873600T3 (pl) 2018-10-29 2024-03-11 Boehringer Ingelheim International Gmbh Pochodne pirydynylosulfonamidu, kompozycje farmaceutyczne i ich zastosowania
CN109705075B (zh) * 2018-12-13 2022-12-23 苏中药业集团股份有限公司 一种达格列净的纯化方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3079175A1 (en) 2019-08-30 2021-02-28 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
JP7441946B2 (ja) 2019-11-28 2024-03-01 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 非ヒト動物の乾乳におけるｓｇｌｔ－２阻害剤の使用
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
WO2021165316A1 (en) 2020-02-21 2021-08-26 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
WO2021214023A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2021219691A1 (en) 2020-04-29 2021-11-04 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
WO2021245253A1 (en) 2020-06-05 2021-12-09 Krka, D.D., Novo Mesto Preparation of highly pure amorphous dapagliflozin
WO2021260617A1 (en) * 2020-06-25 2021-12-30 Hikal Limited An improved process for preparation of dapagliflozin propanediol monohydrate
CA3188345A1 (en) 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
CN116249699A (zh) 2020-09-30 2023-06-09 北京睿创康泰医药研究院有限公司 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
TR202019590A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
WO2022119543A1 (en) 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR202019592A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Amorf dapagliflozinin katı farmasötik formülasyonları
TR202019589A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
EP4079296A1 (en) 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024527434A (ja) 2021-07-28 2024-07-24 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
CN113773194B (zh) 2021-08-16 2023-05-02 浙江奥翔药业股份有限公司 作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
JP2025501336A (ja) 2021-12-30 2025-01-17 ニューアムステルダム ファーマ ベー．フェー． オビセトラピブとｓｇｌｔ２阻害剤との組み合わせ
EP4212150A1 (en) 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
EP4531810A1 (en) 2022-05-25 2025-04-09 Boehringer Ingelheim Vetmedica GmbH Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
CN119325376A (zh) 2022-06-07 2025-01-17 阿斯利康(瑞典)有限公司 Rxfp1调节剂和sglt2抑制剂的组合
KR102490653B1 (ko) * 2022-08-03 2023-01-20 진양제약주식회사 다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
KR20240028315A (ko) 2022-08-24 2024-03-05 주식회사 제뉴원사이언스 다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
US20240307383A1 (en) 2023-02-08 2024-09-19 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of proteinuria chronic kidney disease
EP4427742A1 (en) 2023-03-06 2024-09-11 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
AR132054A1 (es) 2023-03-06 2025-05-21 Boehringer Ingelheim Vetmedica Gmbh Sistemas y métodos para la administración de composiciones farmacéuticas líquidas, en particular que comprenden uno o más inhibidores de sglt-2
EP4431088A1 (en) 2023-03-06 2024-09-18 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
TW202446389A (zh) 2023-04-24 2024-12-01 荷蘭商新阿姆斯特丹製藥公司 非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
EP4487910A1 (en) 2023-07-06 2025-01-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of dapagliflozin
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
EP4556001A1 (en) 2023-11-14 2025-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. A bilayer tablet composition comprising dapagliflozin and metformin
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法
WO2025133907A1 (en) 2023-12-18 2025-06-26 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of microvascular angina
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof
WO2025163559A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Combination of zibotentan and dapagliflozin for use for the treatment of hypertension
CN118908926A (zh) * 2024-07-24 2024-11-08 安徽海康药业股份有限公司 一种达格列净的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444050A (en) * 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03133746A (ja) * 1989-10-19 1991-06-06 Taiyo Kagaku Kogyo Kk 自立袋およびその製造方法
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
EP0671953A4 (en) * 1992-11-13 1996-01-10 Univ Ohio State Res Found C-GLYCOSIDE ANALOG OF N- (HYDROXYPHENYL) RETINAMIDE-O-GLUCURONID.
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
PT850948E (pt) 1996-12-26 2002-08-30 Tanabe Seiyaku Co Derivados propiofenona e processo para a preparacao dos mesmos
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
JP4045364B2 (ja) * 1997-04-04 2008-02-13 田辺三菱製薬株式会社 ２−アミノプロパン−１，３−ジオール化合物、その医薬としての用途およびその合成中間体
JP3451000B2 (ja) 1997-10-20 2003-09-29 新日本製鐵株式会社 方向性珪素鋼板の絶縁皮膜形成方法
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
AUPP823099A0 (en) * 1999-01-18 1999-02-11 Alchemia Pty Ltd Protecting groups for carbohydrate synthesis
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
AU2002254567B2 (en) * 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444050A (en) * 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
KR20200028796A (ko) 2018-09-07 2020-03-17 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물

Also Published As

Publication number Publication date
JP5604568B2 (ja) 2014-10-08
PE20040760A1 (es) 2004-11-20
FR13C0022I1 (fr) 2014-02-03
RU2337916C2 (ru) 2008-11-10
GEP20084403B (en) 2008-06-25
NO329107B1 (no) 2010-08-23
MXPA04011371A (es) 2005-02-14
NO20044915L (no) 2004-12-16
SI1506211T1 (sl) 2007-10-31
RU2489151C2 (ru) 2013-08-10
JP2009275050A (ja) 2009-11-26
BE2014C041I2 (enrdf_load_stackoverflow) 2022-08-09
RU2746132C1 (ru) 2021-04-07
CN101628905B (zh) 2012-03-21
MY142499A (en) 2010-11-30
CN101092409A (zh) 2007-12-26
CY2013013I2 (el) 2015-11-04
NO2013007I1 (no) 2013-04-29
PL210304B1 (pl) 2011-12-30
RU2013115635A (ru) 2014-10-20
TWI310770B (en) 2009-06-11
JP2005531588A (ja) 2005-10-20
AU2003237886B2 (en) 2009-02-05
BR122017015091B8 (pt) 2021-07-27
US6515117B2 (en) 2003-02-04
CN102627676A (zh) 2012-08-08
LTC1506211I2 (lt) 2023-02-10
PL373369A1 (en) 2005-08-22
MX249731B (es) 2007-10-01
CY2014025I1 (el) 2015-11-04
DK1506211T3 (da) 2007-04-10
UA77306C2 (uk) 2006-11-15
IN2004DE03573A (enrdf_load_stackoverflow) 2005-04-01
JP2014028807A (ja) 2014-02-13
DE60311649D1 (de) 2007-03-22
HRP20041084A2 (en) 2005-06-30
LU92182I2 (fr) 2013-06-17
RU2643764C2 (ru) 2018-02-05
RS51469B (en) 2011-04-30
RU2017131447A3 (enrdf_load_stackoverflow) 2021-01-14
NO2014017I1 (no) 2014-07-09
US20020137903A1 (en) 2002-09-26
JP5090621B2 (ja) 2012-12-05
FR13C0022I2 (fr) 2014-03-07
JP2012207037A (ja) 2012-10-25
HRP20041084B1 (hr) 2008-06-30
IS7529A (is) 2004-11-16
RU2643764C9 (ru) 2021-12-15
CN100534997C (zh) 2009-09-02
BR122017015091B1 (pt) 2018-05-15
ES2280759T3 (es) 2007-09-16
HK1068214A1 (en) 2005-04-22
MEP13008A (en) 2010-06-10
LU92496I2 (fr) 2014-09-10
BRPI0311323B8 (pt) 2021-05-25
HK1205120A1 (en) 2015-12-11
BE2013C025I2 (enrdf_load_stackoverflow) 2022-09-29
ATE353334T1 (de) 2007-02-15
ME00091B (me) 2010-10-10
JP5340077B2 (ja) 2013-11-13
RU2004137489A (ru) 2005-06-27
KR20050004161A (ko) 2005-01-12
IL165119A0 (en) 2005-12-18
DE60311649T2 (de) 2007-11-22
CA2486539C (en) 2012-03-13
AU2003237886A1 (en) 2003-12-12
BR0311323A (pt) 2005-03-15
NO2013007I2 (no) 2013-04-12
PT1506211E (pt) 2007-04-30
RU2017131447A (ru) 2019-03-07
WO2003099836A1 (en) 2003-12-04
AR040032A1 (es) 2005-03-09
CA2486539A1 (en) 2003-12-04
CN101628905A (zh) 2010-01-20
LU92182I9 (enrdf_load_stackoverflow) 2019-01-04
CN104230866A (zh) 2014-12-24
RS99204A (en) 2006-12-15
CN102627676B (zh) 2014-08-20
BRPI0311323B1 (pt) 2017-09-26
EP1506211A1 (en) 2005-02-16
JP5584738B2 (ja) 2014-09-03
RU2489151C3 (ru) 2019-11-28
NZ536605A (en) 2007-05-31
CY2014025I2 (el) 2015-11-04
RU2008122558A (ru) 2009-12-20
EP1506211A4 (en) 2005-08-17
NO2022041I1 (no) 2022-10-03
CY2013013I1 (el) 2015-11-04
TW200404813A (en) 2004-04-01
FR14C0054I1 (fr) 2014-08-08
ZA200409295B (en) 2006-02-22
CY1106465T1 (el) 2012-01-25
LTPA2013008I1 (lt) 2013-05-27
EP1506211B1 (en) 2007-02-07
CN1653075A (zh) 2005-08-10
RU2746132C3 (ru) 2021-08-02

Similar Documents

Publication Publication Date Title
KR101021752B1 (ko) Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제 및 억제 방법
KR100728085B1 (ko) Ｃ-아릴 글루코시드 ｓｇｌｔ2 억제제
US20030114390A1 (en) C-aryl glucoside SGLT2 inhibitors and method
RU2800510C1 (ru) С-арил глюкозидные sglt2 ингибиторы и способ их применения
HK1068214B (en) C-aryl glucoside sglt2 inhibitors and method

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140221

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1 2, Period Limitation Text : 238, Comment Text : 5016

St.27 status event code: A-4-4-G10-G18-tex-PA0101

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 2, Claim Number : 1 2, Period Limitation Text : 238, Comment Text : 5016

St.27 status event code: A-4-4-G10-G20-tex-PE0702

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20150130

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

PJ0205 Invalidation trial for registration of extension of term of patent right

St.27 status event code: A-5-5-V10-V11-apl-PJ0205

J121 Written withdrawal of request for trial
J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
J205 Invalidation trial for registration of extension of term of patent right
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

PJ0205 Invalidation trial for registration of extension of term of patent right

St.27 status event code: A-5-5-V10-V11-apl-PJ0205

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

FPAY Annual fee payment

Payment date: 20160127

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PJ0205 Invalidation trial for registration of extension of term of patent right

St.27 status event code: A-5-5-V10-V11-apl-PJ0205

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150320

Effective date: 20160609

Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150403

Effective date: 20160609

PJ1301 Trial decision

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001998

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001995

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001991

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001989

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001933

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001932

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001291

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001288

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001287

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001286

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002007

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002112

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002114

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002122

Decision date: 20160609

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001292

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION OF EXTENSION OF TERM

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150403

Effective date: 20160713

PJ1301 Trial decision

Decision date: 20160713

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002123

Decision date: 20160713

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002124

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100000876; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20160407

Effective date: 20161223

PJ1301 Trial decision

Decision date: 20161223

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 1021752

Appeal request date: 20160407

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100000876

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

FPAY Annual fee payment

Payment date: 20170201

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

T16-X000 Administrative procedure resumed

St.27 status event code: U-5-5-T10-T16-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2016200006760; JUDGMENT (PATENT COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20160912

Effective date: 20180126

PJ1302 Judgment (patent court)

Decision date: 20180126

Decision identifier: 2016200006760

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20152123 (1021752)

Appeal request date: 20160912

Appellate body name: Patent Court

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

PJ1302 Judgment (patent court)

Decision date: 20180126

Decision identifier: 2016200005156

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151286 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005163

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151287 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005170

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151288 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005187

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151292 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005194

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151932 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005798

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20152122 (1021752)

Appeal request date: 20160729

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005804

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20152007 (1021752)

Appeal request date: 20160729

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200006081

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151991 (1021752)

Appeal request date: 20160809

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200006098

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151989 (1021752)

Appeal request date: 20160809

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200006104

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20152112 (1021752)

Appeal request date: 20160809

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200006111

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20152114 (1021752)

Appeal request date: 20160809

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200006128

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151995 (1021752)

Appeal request date: 20160809

Appellate body name: Patent Court

Decision date: 20180126

Decision identifier: 2016200005200

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation of Extension of Term, Appeal Ground Text : 20151933 (1021752)

Appeal request date: 20160708

Appellate body name: Patent Court

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

FPAY Annual fee payment

Payment date: 20190129

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

T15-X000 Administrative procedure interrupted

St.27 status event code: U-5-5-T10-T15-oth-X000

T15-X000 Administrative procedure interrupted

St.27 status event code: U-5-5-T10-T15-oth-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2015100001978; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001974; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001655; TRIAL DECISION FOR INVALIDATION REQUESTED 20150328

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001485; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001499; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001147; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100002016; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001146; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001145; TRIAL DECISION FOR INVALIDATION REQUESTED 20150320

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001476; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001400; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001496; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001566; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001490; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001872; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001917; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001379; TRIAL DECISION FOR INVALIDATION REQUESTED 20150327

Effective date: 20190830

Free format text: TRIAL NUMBER: 2015100001915; TRIAL DECISION FOR INVALIDATION REQUESTED 20150403

Effective date: 20190830

PJ1301 Trial decision

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001499

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001496

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001490

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001485

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001476

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001400

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001379

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001147

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001146

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150320

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001145

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002061

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100002016

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001978

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001974

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001917

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001915

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150403

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001872

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150328

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001655

Decision date: 20190830

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 1021752

Appeal request date: 20150327

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2015100001566

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2019200007863; INVALIDATION

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

FPAY Annual fee payment

Payment date: 20200129

Year of fee payment: 10

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100003881; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100004083; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161219

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003886; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003831; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003880; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003883; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003887; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003830; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003657; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161121

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003857; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100003656; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161121

Effective date: 20200221

Free format text: TRIAL NUMBER: 2016100004084; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161219

Effective date: 20200221

PJ1301 Trial decision

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003857

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161121

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003656

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161121

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003657

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003830

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003831

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161219

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100004084

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003880

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003881

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003883

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003886

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003887

Decision date: 20200221

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161219

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100004083

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100003858; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003828; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003860; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003879; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003829; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003832; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003862; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003833; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161202

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003850; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003851; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

Free format text: TRIAL NUMBER: 2016100003874; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200303

PJ1301 Trial decision

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003874

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003828

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003829

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003832

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161202

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003833

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003850

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003851

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003858

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003860

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003862

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003879

Decision date: 20200303

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003885

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100003871; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200507

Free format text: TRIAL NUMBER: 2016100003873; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200507

Free format text: TRIAL NUMBER: 2016100003865; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200507

Free format text: TRIAL NUMBER: 2016100003876; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161205

Effective date: 20200507

PJ1301 Trial decision

Decision date: 20200507

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003871

Decision date: 20200507

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003865

Decision date: 20200507

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003873

Decision date: 20200507

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20161205

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2016100003876

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

J301 Trial decision

Free format text: TRIAL NUMBER: 2017100001993; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170628

Effective date: 20200623

PJ1301 Trial decision

Decision date: 20200623

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20170628

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2017100001993

Decision date: 20200623

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 1021752

Appeal request date: 20180417

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2018100001184

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

PJ2001 Appeal

St.27 status event code: A-5-5-V10-V12-crt-PJ2001

PJ2002 Appeal before the supreme court

St.27 status event code: A-5-5-V10-V12-crt-PJ2002

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ1201

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC2102 Extinguishment

St.27 status event code: N-4-6-H10-H13-oth-PC2102

J122 Written withdrawal of action (patent court)
J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2019200007863; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20191104

Effective date: 20201029

PJ1202 Withdrawal of action (patent court)

St.27 status event code: A-5-5-V10-V13-crt-PJ1202

PJ1302 Judgment (patent court)

Decision date: 20201029

Decision identifier: 2019200007863

Decision authority category: National patent court

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 20151145 (1021752)

Appeal request date: 20191104

Appellate body name: Patent Court

St.27 status event code: A-5-5-V10-V15-crt-PJ1302

PJ1303 Judgment (supreme court)

Decision date: 20230202

Decision authority category: Court of appeal

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 2019 7863 (1021752)

Appeal request date: 20201125

Appellate body name: Supreme Court

Decision identifier: 2020300011738

Decision text: .(1021752 .) : 20151145, 20151146 , 20151147 , 20151379 , 20151400 , 20151476 , 20151485 , 20151490 , 20151496 , 20151499 , 20151566 , 20151655 , 20151872 , 20151915 , 20151917 , 20151974 , 20151978 20152016 , 20152061

St.27 status event code: A-5-5-V10-V15-crt-PJ1303